Shares of AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) saw unusually-strong trading volume on Friday . Approximately 651,802 shares traded hands during trading, an increase of 185% from the previous session’s volume of 228,542 shares.The stock last traded at $3.47 and had previously closed at $3.08.

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of AcelRx Pharmaceuticals in a report on Tuesday, May 3rd. Jefferies Group reaffirmed a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Friday, June 10th. Seaport Global Securities raised AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Friday, May 6th. Cowen and Company reaffirmed a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Friday. Finally, Janney Montgomery Scott assumed coverage on AcelRx Pharmaceuticals in a report on Thursday, April 14th. They issued a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $7.63.

The firm’s 50 day moving average is $2.92 and its 200 day moving average is $3.31. The company’s market capitalization is $164.48 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings results on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The business earned $4.53 million during the quarter, compared to analysts’ expectations of $2.17 million. Equities analysts expect that AcelRx Pharmaceuticals Inc. will post ($0.89) EPS for the current year.

In other AcelRx Pharmaceuticals news, Director Mark G. Edwards purchased 15,000 shares of the stock in a transaction on Thursday, May 12th. The shares were purchased at an average price of $3.15 per share, with a total value of $47,250.00. Following the acquisition, the director now directly owns 105,000 shares in the company, valued at approximately $330,750. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Howard B. Rosen acquired 10,206 shares of the firm’s stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average cost of $3.26 per share, for a total transaction of $33,271.56. Following the completion of the acquisition, the chief executive officer now owns 50,000 shares in the company, valued at approximately $163,000. The disclosure for this purchase can be found here.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.